기사
[PDF] Increasing people’s access to essential medicines in developing countries: a framework for good practice in the pharmaceutical industry
Responsibility for increasing access to essential medicines rests with the whole international community...In this context there is a particular role for pharmaceutical companies. As the producers of existing, and developers of new, medicines they can – and do – make a difference within their sphere of influence. [refers to Novartis, GlaxoSmithKline, Merck, Roche, Ranbaxy Laboratories, AstraZeneca, Tibotec (part of Johnson & Johnson), Eli Lilly, Pfizer, Shire Pharmaceuticals]